Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings-Reference-Cited by-同舟云学术

Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings

Published:2021-10 Issue: Volume:55 Page:103146
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Rimkus Carolina M,Schoeps Vinicius Andreoli,Boaventura Mateus,Godoy Luis Filipe,Apostolos-Pereira Samira Luisa,Calich Ana Luisa,Callegaro Dagoberto,Lucato Leandro Tavares,Rovira Alex,Sastre-Garriga Jaume,Leite Claudia da Costa

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference80 articles.

1. Iatrogenic demyelinating disorders: New insights, new culprits;Abboud;Mult. Scler.,2020

2. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients;Alping;Ann. Neurol.,2016

3. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations;Barry;Neurol Ther,2019

4. MS arising during Tocilizumab therapy for rheumatoid arthritis;Beauchemin;Mult. Scler.,2016

5. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation;Berger;J. Neuroimmunol.,2015

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atypical Demyelinating Disorders;Neuroimaging Clinics of North America;2024-08

2. John Cunningham Virus and Progressive Multifocal Leukoencephalopathy: A Falsely Played Diagnosis;Diseases;2024-05-13

3. Global burden of vaccine‐associated multiple sclerosis, 1967–2022: A comprehensive analysis of the international pharmacovigilance database;Journal of Medical Virology;2024-04

4. Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma;Neurological Sciences;2023-12-13

5. Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study;Frontiers in Pharmacology;2023-10-10